Biomarkers Leaders Should Measure After 35
Biomarkers Leaders Should Measure After 35
The Biological Shifts That Are Already Underway, and the Measurements That Let You Act Before They Become Irreversible
Between 35 and 50, your body begins a process that is largely invisible, mostly painless, and if left unmonitored, increasingly irreversible. Feeling fine is not a health strategy. It is a lag indicator.
Between 35 and 50, your body begins a process that is largely invisible, mostly painless, and if left unmonitored, increasingly irreversible. You will not feel your testosterone declining. You will not notice the moment your mitochondria begin producing energy less efficiently. You will not sense your immune system losing its ability to clear damaged, inflammatory cells. But all of it is happening. And in executives operating under chronic cognitive load, disrupted sleep, and caloric surplus, it happens faster.
The Biological Debt
There is a concept worth naming directly: biological debt. It is the gap between the damage your body accumulates day-to-day, from stress hormones, oxidative load, inflammatory exposure, and cellular senescence, and the body’s capacity to repair that damage. In your twenties, repair outpaces damage. After 35, the equation begins to invert.
Hormonal Decline
Testosterone in men drops at approximately 1 to 2% per year after 30: a figure that compounds meaningfully by the time you are 42 and running a 400-person organisation. For women, the perimenopausal transition, which can begin as early as the late 30s, brings shifts in oestrogen and progesterone that directly affect sleep architecture, mood regulation, and metabolic rate.
Mitochondrial Inefficiency
Mitochondria, the organelles responsible for producing cellular energy, begin to function less efficiently with age. Declining mitochondrial efficiency is linked to cognitive fatigue, slower processing speed, and reduced capacity for sustained attention: precisely the functions executives depend on most.
Senescent Cell Accumulation
Senescent cells, sometimes called “zombie cells,” accumulate in tissues. These are cells that have stopped dividing but refuse to die. They secrete a cocktail of inflammatory molecules known as the senescence-associated secretory phenotype (SASP) that accelerates ageing in surrounding tissue and is increasingly associated with cardiovascular disease, metabolic dysfunction, and neurodegeneration. The body’s immune system normally clears these cells. That clearance capacity declines with age and with chronic stress.
Why Executives Are at Accelerated Risk
The standard lifestyle of a high-performing executive is, from a biological standpoint, a stress multiplier. Three compounding mechanisms drive accelerated biological ageing in this population specifically.
The Invisible Risk
The executives most at risk are not the ones in obvious crisis. They are the ones who are performing adequately, but whose biological trajectory, unmeasured, is quietly eroding the ceiling on what “adequate” will look like at 48 or 52.
Chronic sleep restriction elevates cortisol, suppresses testosterone, and accelerates cellular ageing. Research confirms leaders who consistently sleep under six hours carry a measurable decision-making deficit they cannot subjectively detect.
Silent Degradation
The Compounding Mechanisms
Caloric abundance without nutritional precision creates metabolic noise: elevated insulin, chronic low-grade inflammation, and impaired glucose regulation that compounds hormonal decline.
Sustained psychological stress dysregulates the HPA axis and drives cortisol chronically high, directly suppressing anabolic hormones, compromising immune function, and accelerating hippocampal atrophy.
Three Multipliers, One Trajectory
What to Measure: Biological Systems
These are the functional systems that determine performance capacity and long-term health trajectory. They should be assessed through structured testing, not self-report.
VO2 Max
The single most predictive biomarker for all-cause mortality in the published literature. It measures cardiorespiratory fitness: how efficiently your body delivers and uses oxygen under demand. In executives, it also correlates with cognitive processing speed and recovery from stress. A VO2 Max in the “superior” range for your age bracket is not about athletics. It is about physiological resilience.
Testosterone (Men) and Muscle Mass (Women)
In men, testosterone governs energy, motivation, competitive drive, and cognitive sharpness. Low testosterone does not announce itself dramatically: it presents as a slow flattening of drive, a subtle reduction in decisiveness, and a creeping fatigue that is easy to attribute to “the job.” In women, muscle mass becomes the critical proxy for metabolic health and hormonal balance, particularly in the perimenopausal phase. Loss of lean mass accelerates insulin resistance and is directly linked to cognitive decline.
Mitochondrial Efficiency
Assessed through metabolic testing and markers like lactate threshold and resting metabolic rate, this tells you how well your cells are actually producing energy. Poor mitochondrial function is the hidden driver of brain fog, post-meeting cognitive fatigue, and the inexplicable drop in output after 3 PM that no amount of caffeine reliably fixes.
Cognitive Processing Speed
Measurable through validated neuropsychological assessments. Tracks reaction time, working memory, and executive function over time. Establishes a personal baseline so decline, if it occurs, is detected early and addressed rather than rationalised.
Immune Senolytic Capacity
An emerging but increasingly accessible measure of how effectively the immune system is clearing senescent cells. Elevated inflammatory markers alongside declining immune markers signal accumulation of cellular debris driving silent inflammation.
Bone Mineral Density
Critical for both men and women after 40, and systematically under-screened in executives. Bone density decline is silent until it is catastrophic. It is also directly modifiable through resistance training and nutritional intervention, but only if you know where you stand.
What to Measure: Blood Biomarkers
The standard annual blood panel is not enough. It tells you whether you are in a crisis. It does not tell you where you are trending. The following markers form a meaningful cardiovascular and metabolic panel for executives over 35.
ApoB (Apolipoprotein B)
The most direct measure of atherogenic particle concentration: the particles that cause plaque. Standard LDL-C misses this. Leading cardiologists have argued for decades that ApoB is the marker the field should have been prioritising. Every leader over 35 should know their ApoB number.
LDL-C
Still useful, particularly in conjunction with ApoB and Lp(a). Understand that LDL particle number as measured by ApoB matters more than LDL cholesterol concentration alone.
Lp(a), Lipoprotein(a)
Genetically determined and largely unresponsive to lifestyle intervention. Elevated Lp(a) is one of the most underdiagnosed independent risk factors for early cardiovascular events. It needs to be tested once. If elevated, the clinical strategy around all other markers changes significantly.
hsCRP, High-Sensitivity C-Reactive Protein
The primary marker of systemic, low-grade inflammation. Chronically elevated hsCRP signals that the immune system is fighting something it cannot resolve, whether that is poor sleep, visceral fat, gut dysbiosis, or early cardiovascular pathology.
GlycA
A more stable inflammatory marker than hsCRP, which can fluctuate daily. GlycA measures the glycosylation of acute-phase proteins and provides a longer-term signal of inflammatory burden. It is increasingly available through advanced lipid panels.
Triglycerides
Triglycerides are the metabolic fingerprint of how well your body handles carbohydrates and alcohol. Elevated triglycerides, particularly with low HDL, signal metabolic dysfunction that precedes formal Type 2 Diabetes diagnosis by years or decades.
Fasting Insulin
Almost never tested on a standard panel. Fasting insulin is the earliest warning signal of insulin resistance, detectable years before blood glucose becomes abnormal. By the time fasting glucose elevates, insulin resistance is already well established. Test this annually.
HDL-C
Not just a “good cholesterol” number. In combination with ApoB, Lp(a), and triglycerides, HDL-C tells a story about reverse cholesterol transport and metabolic health. Chronically low HDL in executives correlates with both cardiovascular risk and impaired cognitive function.
The Rational Response
The leaders who will outperform over the next decade are not the ones who work harder. They are the ones who understand that performance has a biological substrate, and that substrate can be measured, managed, and compounded.
The alternative is to continue operating on the assumption that feeling well means functioning well, and that the body will signal its problems before they become irreversible. It often does not.
If you are between 35 and 50 and operating in a high-cognitive-load environment, the panel above is not optional maintenance. It is risk management.
Executive Health and Performance Advisory
You measure every high-stakes system you manage. Your biology should not be the exception.
Deep-Health works with founders and senior executives over 35 to establish a comprehensive biological baseline, track the markers that standard panels miss, and build the clinical framework that intervenes before the trajectory becomes irreversible.
Explore Executive AdvisoryDisclaimer
The information presented in this article is intended for educational purposes and does not constitute medical advice. Biomarker ranges, risk associations, and intervention recommendations reflect published clinical literature available at the time of writing. Individual biological profiles vary significantly and no single marker should be interpreted in isolation. Any decision to pursue additional testing, clinical assessment, or intervention should involve consultation with a qualified physician. Deep-Health does not provide diagnosis or prescribe interventions without prior individual assessment. This content reflects the author’s analysis based on clinical literature and professional experience working with executives and founders.
Sanjay Dev
Founder of Deep-Health. 20-plus years working with founders, executives, athletes, and organisations at the intersection of neuroscience, physiology, and behavioural biochemistry.
View all articles by Sanjay